Orbsen Therapeutics Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
7
Orbsen Therapeutics General Information
Description
Operator of a regenerative medicine company intended to promote the healing, repair, and regeneration of damaged tissues. The company develops ground-breaking stromal cell treatments to address heart disease, arterial disease of the limbs, diabetes complications, arthritis, and other inflammatory conditions, enabling patients to get cured of rare medical syndromes.
Contact Information
Website
www.orbsentherapeutics.comCorporate Office
- Orbsen Building, NUIG
- University Road
- Galway H91 TK33
- Ireland
Corporate Office
- Orbsen Building, NUIG
- University Road
- Galway H91 TK33
- Ireland
Orbsen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orbsen Therapeutics Comparisons
Industry
Financing
Details
Orbsen Therapeutics Competitors (109)
One of Orbsen Therapeutics’s 109 competitors is Regenerx, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| AlgoTx | Venture Capital-Backed | Suresnes, France | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom |
Orbsen Therapeutics Patents
Orbsen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260335374-A1 | Compositions and methods for treating kidney disease | Pending | 13-Oct-2022 | ||
| AU-2023361649-A1 | Scd2+ stromal cells for treating diabetic kidney disease | Pending | 13-Oct-2022 | ||
| EP-4601661-A1 | Scd2+ stromal cells for treating diabetic kidney disease | Pending | 13-Oct-2022 | ||
| WO-2024079524-A1 | Scd2+ stromal cells for treating diabetic kidney disease | Inactive | 13-Oct-2022 | ||
| EP-4017512-A1 | Compositions for monocyte and macrophage polarization and methods of use | Active | 23-Aug-2019 | A61K35/28 |
Orbsen Therapeutics Signals
Orbsen Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Orbsen Therapeutics FAQs
-
When was Orbsen Therapeutics founded?
Orbsen Therapeutics was founded in 2006.
-
Where is Orbsen Therapeutics headquartered?
Orbsen Therapeutics is headquartered in Galway, Ireland.
-
What is the size of Orbsen Therapeutics?
Orbsen Therapeutics has 12 total employees.
-
What industry is Orbsen Therapeutics in?
Orbsen Therapeutics’s primary industry is Drug Discovery.
-
Is Orbsen Therapeutics a private or public company?
Orbsen Therapeutics is a Private company.
-
What is Orbsen Therapeutics’s current revenue?
The current revenue for Orbsen Therapeutics is .
-
How much funding has Orbsen Therapeutics raised over time?
Orbsen Therapeutics has raised $3.9M.
-
Who are Orbsen Therapeutics’s investors?
Horizon 2020 and The BioHub Birmingham have invested in Orbsen Therapeutics.
-
Who are Orbsen Therapeutics’s competitors?
Regenerx, Inovio Pharmaceuticals, Verona Pharma, AlgoTx, and Orchard Therapeutics are some of the 109 competitors of Orbsen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process